参考文献/References:
［1］ Dasararaju R， Singh N， Mehta A. Heparin induced thrombocy- topenia： review［J］. Expert Rev Hematol， 2013， 6： 419- 428.［2］ Lovecchio F. Heparin- induced thrombocytopenia［J］. Clin Toxicol （Phila）， 2014， 52： 579- 583.
［3］ Rollin J， Pouplard C， Gruel Y. Risk factors for heparin- induced thrombocytopenia： Focus on Fcγ receptors［J］. Thromb Haemost， 2016， 116： 799- 805.
［4］ Prandoni P， Siragusa S， Girolami B， et al. The incidence of heparin- induced thrombocytopenia in medical patients treated with low- molecular- weight heparin： a prospective cohort study［J］. Blood， 2005， 106： 3049- 3054.
［5］ Stein PD， Hull RD， Matta F， et al. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism［J］. Am J Med， 2009， 122： 919- 930.
［6］ Martel N， Lee J， Wells PS. Risk for heparin- induced thrombocy- topenia with unfractionated and low- molecular- weight heparin thromboprophylaxis： a meta- analysis［J］. Blood， 2005， 106： 2710- 2715.
［7］ Zaman S， Wiebe S， Bernal W， et al. Increased prevalence of heparin- induced thrombocytopenia in patients with Budd- Chiari syndrome： a retrospective analysis［J］. Eur J Gastroenterol Hepatol， 2016， 28： 967- 971.
［8］ 刘 超， 张庆辉， 吴 刚， 等． 肝素诱发血小板减少症1例［J］． 介入放射学杂志， 2016， 25： 133- 135．
［9］ Baroletti S， Hurwitz S， Conti NA， et al. Thrombosis in suspected heparin- induced thrombocytopenia occurs more often with high antibody levels［J］. Am J Med， 2012， 125： 44- 49.
［10］ Linkins LA， Bates SM， Lee AY， et al. Combination of 4Ts score and PF4/H- PaGIA for diagnosis and management of heparin
- induced thrombocytopenia： prospective cohort study［J］. Blood， 2015， 126： 597- 603.
［11］ Cuker A， Arepally G， Crowther MA， et al. The HIT expert probability（HEP） score： a novel pre- test probability model for heparin- induced thrombocytopenia based on broad expert opinion［J］. J Thromb Haemost， 2010， 8： 2642- 2650.
［12］ Messmore HL， Fabbrini N， Bird ML， et al. Simple scoring system for early management of heparin- induced thrombocytopenia［J］. Clin Appl Thromb Hemost， 2011， 17： 197- 201.
［13］ Padmanabhan A， Jones CG， Curtis BR， et al. A novel PF4- dependent platelet activation assay identifies patients likely to have heparin- induced thrombocytopenia/thrombosis［J］. Chest， 2016， 150： 506- 515.
［14］ Sachs UJ， von Hesberg J， Santoso S， et al. Evaluation of a new nanoparticle- based lateral- flow immunoassay for the exclusion of heparin- induced thrombocytopenia （HIT）［J］. Thromb Haemost， 2011， 106： 1197- 1202.
［15］ Nazi I， Arnold DM， Smith JW， et al. FcγRⅡa proteolysis as a diagnostic biomarker for heparin- induced thrombocytopenia［J］. J Thromb Haemost， 2013， 11： 1146- 1153.
［16］ Greinacher A， Farner B， Kroll H， et al. Clinical features of heparin- induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients［J］. Thromb Haemost， 2005， 94： 132- 135.
［17］ 梁晓东， 王子亮， 李天晓， 等． 替罗非班诱导重度血小板减少伴贫血1例［J］． 介入放射学杂志， 2016， 25： 580- 581．
［18］ Cuker A. Heparin- induced thrombocytopenia （HIT） in 2011： an epidemic of overdiagnosis［J］. Thromb Haemost， 2011， 106： 993- 994.
［19］ Cardenas GA， Deitcher SR. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin- induced thrombocytopenia［J］. Mayo Clin Proc， 2005， 80： 491- 493.
［20］ Tardy- Poncet B， Wolf M， Lasne D， et al. Danaparoid cross- reactivity with heparin- induced thrombocytopenia antibodies： report of 12 cases［J］. Intensive Care Med， 2009， 35： 1449- 1453.
［21］ Tardy- Poncet B， Nguyen P， Thiranos JC， et al. Argatroban in the management of heparin- induced thrombocytopenia： a multi- center clinical trial［J］. Crit Care， 2015， 19： 396.
［22］ Aljabri A， Huckleberry Y， Karnes JH， et al. Cost- effectiveness of anticoagulants for suspected heparin- induced thrombocytopenia in the United States［J］. Blood， 2016， 128： 3043- 3051.
［23］ Linkins LA， Dans AL， Moores LK， et al. Treatment and prevention of heparin- induced thrombocytopenia： Antithrombotic Therapy and Prevention of Thrombosis， 9th ed： American College of Chest Physicians Evidence- Based Clinical Practice Guidelines［J］. Chest， 2012， 141（2 Suppl）： e495S- e530S.
［24］ Al- Lamee RK， Gerber RT， Kooner JS. Heparin- induced thrombocy- topenia（HIT） as an unusual cause of acute stent thrombosis［J］. Eur Heart J， 2010， 31： 613.
［25］ Koster A， Sanger S， Hansen R， et al. Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices［J］. ASAIO J， 2000， 46： 319- 322.
［26］ Naganuma T， Mitomo S， Kin N， et al. Successful anticoagulation using argatroban during transcatheter aortic valve implantation in a patient with heparin- induced thrombocytopenia［J］. AA Case Rep， 2016， 7： 158- 160.
［27］ Devesa- Cordero C， Sousa- Casasnovas I， Martinez- Selles M， et al. Lethal heparin- induced thrombocytopenia after transfemoral aortic valve implantation［J］. Int J Cardiol， 2016， 223： 95- 97.［28］ Lee SK， Willinsky R， Terbrugge K. Dural sinus thrombosis complicated with heparin induced thrombocytopenia and thrombosis （HITT）［J］. Interv Neuroradiol， 2002， 8： 77- 80.
［29］ van Sambeek MR， Segeren CM， van Dijk LC， et al. Endovascular repair of an extracranial internal carotid artery aneurysm complicated by heparin- induced thrombocytopenia and thrombosis［J］. J Endovasc Ther， 2000， 7： 353- 358.
［30］ Stotts G， Skinner C， Code C， et al. Acute stent occlusion due to heparin induced thrombocytopenia and thrombosis during carotid artery stenting［J］. J Neurointerv Surg， 2012， 4： e34.
［31］ Blas JV. Carsten CG 3rd，Gray BH. Heparin- induced thrombocy- topenia associated with a heparin- bonded stent graft［J］. Ann Vasc Surg， 2016， 33： 227.e1- e4.
［32］ Canaud L， Hireche K， Marty- Ane C， et al. Heparin- induced thrombocytopenia with abdominal aortic stent- graft acute thrombosis［J］. Ann Vasc Surg， 2013， 27： 801.e5- 801.e7.
［33］ 田玉龙， 张曦彤． 下肢深静脉血栓介入治疗发生肝素诱发血小板减少伴血栓形成综合征一例［J］． 介入放射学杂志， 2012， 21： 53- 54．
［34］ Kasirajan K. Outcomes after heparin- induced thrombocytopenia in patients with propaten vascular grafts［J］. Ann Vasc Surg， 2012， 26： 802- 808.
［35］ Bakchoul T， Jouni R， Warkentin TE. Protamine（heparin）- induced thrombocytopenia： a review of the serological and clinical features associated with anti- protamine/heparin antibodies［J］. J Thromb Haemost， 2016， 14： 1685- 1695.
相似文献/References:
[1].全国布-加综合征专题及介入新技术研讨会征文通知[J].介入放射学杂志,2000,(01):34.
[2]王 颖,张曦彤. 下肢深静脉血栓形成介入治疗后复发的危险因素分析[J].介入放射学杂志,2013,(09):764.
WANG Ying,ZHANG Xi? tong.. Analysis of the risk factors influencing the recurrence of deep venous thrombosis in lower extremity after interventional treatment[J].journal interventional radiology,2013,(05):764.